Welcome on the Necker-Enfants Malades Institute website
  • Group leader positions at Institut Necker Enfants Malades, Université Paris Cité, Paris-France
    The Institut Necker Enfants Malades (INEM, https://www.institut-necker-enfants-malades.fr/) invites applications for two group leader positions. Excellent future prospects and an upwards-scientific track record will be the principal selection criteria. We promote equal opportunities, strongly [...]
  • Summer School on Pharmaceutical medicine (July 3 - 6, 2023)
    The school is being developed as part of the TrainCKDis network (Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery; www.trainckdis.eu): a European innovative, multidisciplinary, and intersectoral training programme to prepare the next [...]
  • Prestige Lectures at INEM
    Hans Clevers is a Dutch molecular geneticist, cell biologist and stem cell researcher. Hans is currently the Head of pharma Research and Early Development (pRED), and a member of the Corporate Executive Committee of F. Hoffmann-La Roche based in Basel, Switzerland. Previously, Hans headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at [...]
  • Identification of AKT-FoxO1 as an on/off gate for marginal zone B cell development
    The team of Simon Fillatreau identified in a collaborative work with the team of Dr. Nadine Hövelmeyer (Mainz University, Germany) the chief role of the AKT-FoxO1 signaling axis in the formation of mouse and human marginal zone B cells, which are involved in host defense against encapsulated bacteria (Cell Reports,
  • Just published in JCI Insight
    Just published in JCI Insight: the team of Marco Pontoglio and the team of Fabiola Terzi, in collaboration with the pathology department of Necker hospital, have elucidated two key events in the pathophysiology of kidney damage in patients with COVID-19: (1) they demonstrated that SARS-CoV-2 infects living renal cells and that the infection is associated with increased [...]
  • Exploiter le 5\'super-enhancer de TAL1 dépendant de MYB pour une thérapie ciblée dans la LAL-T.
    L'acquisition d'anomalies génétiques entraînant une dérégulation des oncogènes est à la base du développement du cancer. Certains proto-oncogènes possèdent plusieurs [...]
The Institute
The Institut Necker-Enfants Malades (INEM), created in January 2014, is an international biomedical research center located on the Necker Hospital campus, and supported by the French National Institute of Health and Medical Research (INSERM), the French National Center for Scientific Research (CNRS) and the University of Paris.

Research at INEM is focusing on common diseases caused by the interplay of polygenic inheritance and environmental factors. These diseases primarily affect children and the young, and encompass (auto)immune disorders, haematological diseases, infectious diseases, kidney diseases, cystic fibrosis, endocrinological disorders and metabolic diseases. The INEM teams apply insights obtained through basic and clinical research to develop innovative diagnostic and therapeutic strategies.

For over 40 years, the development of renal transplants and bone marrow transplants, the phenotyping of autoimmune diseases and genetic diseases, allowed most of the major medical advances of today. The major asset of the Institute Necker-Enfants Malades comes from the plurality of skills, the freedom and creativity of its researchers, their desire to diversify their research topics.

Translational activities will be pursued and promoted as much as possible. Indeed, this group of PIs has filed 24 patents, 4 of which are licenced to pharmaceutical companies. 13 R&D contracts have been signed with industry and 3 start-up companies incorporated with one of the above PIs as founder. To further strengthen the link with the socio-economic world, we intend to devote one floor of our research building to hosting private entities, either small companies or teams from bigger pharmaceutical industries wishing to collaborate with groups of the Necker-Enfants Malades Institute.

Our mission

The close interaction between the research labs and the clinical departments is one of our major strengths creating a highly dynamic environment and promoting translational and “bench to bedside” activities. Our research programs are consistent with this mission and most groups have very tight connections with the clinics, mostly through clinicians with joint appointments in research labs and clinical departments.

Our research in the coming years will focus on:
  • Understanding the molecular mechanisms of leukemia is to use targeted therapies and avoid chemotherapy whose collateral damage is known
  • Defeating diabetes, especially the type 1 in children (440,000 in the world), is to address the treatment of autoimmune diseases, more and more frequent in developed countries, as the case for multiple sclerosis or lupus.
  • Succeed one day to control the immune system, thanks to the long experience and considerable clinical material at the Necker hospital on kidney and bone marrow transplantations, is a priority
  • Seek to determine the mechanisms responsible for bacterial meningitis, debilitating in a few hours a perfectly healthy child or subject, is essential to develop effective and safe vaccines.
  • Apply our knowledge of metabolism and growth to promote innovative and personalized therapies in the field of kidney disease, diabetes, cystic fibrosis, muscular dystrophy and various solid tumors.
The Necker-Enfants Malades Institute is administered by one Director assisted by the two department Heads and one General secretary in charge the administration. Each PI or CoPI is responsible for his (her) scientific project and for the use of his (her) allocated space
Fabiola Terzi
INEM Director
Mario Pende
Marco Pontoglio
Director of "Growth and Signalling" Dept
Peter Van Endert
Simon Fillatreau
Director of "Immunology, Infectiology and Haematology" (I2H) Dept
Sabine Barbut
General Secretary
The scientific teams
The people of INEM

Thirteen research teams are founding members of the Necker-Enfants Malades Institute, which comprises today 20 research teams. The teams are grouped in two departments: a department of Cell biology (Growth and Signalling) and a department of, Immunology, Infectiology and Haematology (I2H).

The Necker-Enfants Malades Institute currently comprises 103 senior scientists, one third of whom are medical doctors, 60 technicians and engineers, 35 postdoctoral fellows and 37 PhD students. Among the 19 teams, 7 have already obtained an award from the European Research Council.

Scientific Advisory Board
The Scientific Advisory Board (SAB) is composed of 8 international scientific personalities, experts in their field. Its role will be to advise the INEM on scientific orientations and the recruitment of new groups. If necessary, the SAB might be consulted for strategic decisions. 
Anna Katharina (Katja) Simon
Cédric Blanpain
Sarah-Maria Fendt
Stefan H.E. Kaufmann
Stephen Lory
Helen McNeill
Marco Sandri
Kenneth Smith
Contact us
Institut Necker Enfants Malades

Faculté de Médecine Necker
160, rue de Vaugirard
75015 Paris Cedex
HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

INEM - Organigramme